Knee osteoarthritis is a chronic joint condition that may cause pain, stiffness, swelling, and reduced mobility. Foundational management often includes education, exercise, physical therapy, weight management where appropriate, activity modification, bracing, topical therapies, and simple analgesics. Some patients continue to experience symptoms despite these measures.

Synvisc-One is a single-injection viscosupplement used by qualified healthcare professionals for selected patients with osteoarthritis pain of the knee. It should be positioned as one possible option within a broader knee OA management plan, not as a cure for osteoarthritis or a replacement for clinical assessment.

This guide reviews Synvisc-One’s mechanism of action, hylan G-F 20 formulation, patient-selection considerations, expected treatment experience, safety profile, sourcing considerations, and responsible use for qualified clinics and licensed healthcare professionals.

View professional orthopedic injectables available from Health Supplies Plus.

Key Takeaways

What Is Synvisc-One?

Synvisc-One is an intra-articular viscosupplement used for treatment of osteoarthritis pain in the knee. It contains hylan G-F 20, a form of hyaluronan designed to supplement the viscoelastic properties of synovial fluid.

In a healthy knee, synovial fluid helps lubricate and cushion the joint during movement. In osteoarthritis, the quality and quantity of hyaluronan in joint fluid may change, which can contribute to pain, stiffness, and reduced shock absorption.

Synvisc-One is injected directly into the knee joint by a qualified healthcare professional. It should not be self-administered or used without appropriate diagnosis, patient assessment, and sterile technique.

How Synvisc-One Works

Synvisc-One is used as a viscosupplement. Its purpose is to supplement the joint fluid in the affected knee and support lubrication and shock absorption.

Potential treatment-planning effects may include:

• Lubrication support: Helping joint surfaces move more smoothly.
• Cushioning support: Supporting the shock-absorbing properties of synovial fluid.
• Symptom management: Helping reduce pain in selected patients with knee OA.
• Functional support: Helping some patients participate more comfortably in daily activities or rehabilitation plans.

Synvisc-One should not be described as rebuilding cartilage, reversing arthritis, or modifying the underlying disease process. It is a symptom-management option for selected patients.

Synvisc-One Indication and Clinical Positioning

Synvisc-One is indicated for the treatment of pain in osteoarthritis of the knee in patients who have not achieved adequate relief from conservative non-pharmacological therapy and simple analgesics, such as acetaminophen.

It may be considered when patients have persistent knee OA pain despite appropriate conservative management and are seeking a non-surgical treatment option. However, intra-articular hyaluronic acid injections are not recommended for routine use in every knee OA patient by all clinical guidelines, so patient selection and shared decision-making are important.

Clinics should position Synvisc-One as a selected-patient treatment option that requires medical assessment, informed consent, and realistic expectations.

Potential Benefits of Synvisc-One

For appropriate patients, Synvisc-One may offer several practical treatment-planning benefits.

• Single-injection format: Synvisc-One may reduce the number of injection visits compared with multi-injection HA regimens.
• Localized treatment: The product is injected directly into the knee joint by a qualified professional.
• Potential pain reduction: Some patients may experience improvement in knee OA pain after treatment.
• Functional support: Reduced pain may help some patients continue daily activities or physical therapy more comfortably.
• Non-steroid option: Synvisc-One is not a corticosteroid and has a different treatment role from steroid injections.

Clinics should avoid promising guaranteed pain relief, restored mobility, or a fixed duration of benefit. Patient outcomes vary.

Patient Selection for Synvisc-One

Patient selection is essential. Synvisc-One may be appropriate for selected patients with symptomatic knee osteoarthritis who have not responded adequately to conservative treatment.

Potential candidates may include patients who have:

• Diagnosed osteoarthritis of the knee
• Persistent knee pain despite conservative care
• Inadequate relief from simple analgesics where appropriate
• Preference for non-surgical treatment options
• Realistic expectations about symptom management
• No contraindications based on medical history, allergy history, or joint status

Synvisc-One may be less appropriate for patients whose symptoms are caused by another diagnosis, severe acute inflammatory flare, infection, significant mechanical derangement, advanced structural collapse requiring surgical evaluation, or unrealistic expectations about treatment outcomes.

Contraindications and Precautions

Synvisc-One should only be used after medical assessment. Current product labeling and local protocols should guide final patient selection.

Synvisc-One should not be used in patients with:

• Known hypersensitivity to hyaluronan products
• Knee joint infection
• Skin disease, infection, or inflammation at or near the injection site
• Known hypersensitivity to any component of the product

Additional caution may be needed in patients with:

• Allergy to avian proteins, feathers, eggs, or poultry
• Venous or lymphatic stasis in the leg to be treated
• Severe inflammation in the knee to be treated
• Bleeding disorders or anticoagulant therapy
• Pregnancy or breastfeeding considerations
• Pediatric patients

Patients should not stop prescribed anticoagulants, antiplatelet medicines, or other medications unless advised by the appropriate healthcare provider.

Treatment Planning and Administration

Synvisc-One is administered as an intra-articular knee injection in a clinical setting. The procedure should be performed only by qualified healthcare professionals trained in joint injection technique and aseptic practice.

A responsible treatment workflow may include:

• Diagnosis confirmation and assessment of knee OA severity
• Review of prior treatments and patient goals
• Medical history, allergy, and medication review
• Assessment for infection, effusion, inflammation, or other contraindications
• Discussion of expected benefits, limitations, alternatives, and risks
• Informed consent
• Aseptic intra-articular administration by a qualified clinician
• Written post-injection instructions and follow-up guidance

Detailed injection technique, imaging use, aspiration decisions, and post-procedure protocol should follow current product labeling, professional training, and clinic standards. General marketing content should not be used as a substitute for clinical training or manufacturer instructions.

Expected Results and Timeline

Patients should understand that Synvisc-One is not an immediate cure for knee OA. Symptom response may develop gradually, and not every patient experiences meaningful improvement.

Some patients may experience symptom relief for up to six months after treatment. Others may have a shorter duration of benefit or limited response. Outcomes depend on osteoarthritis severity, joint mechanics, activity level, weight, comorbidities, rehabilitation, and individual response.

Clinics should set realistic expectations and encourage patients to continue appropriate conservative care, including exercise and physical therapy recommendations when clinically appropriate.

Post-Injection Care

Post-injection instructions should be provided in writing and tailored to the patient. Depending on clinician guidance and product labeling, patients may be advised to:

• Avoid strenuous or high-impact activity for a short period after injection
• Avoid prolonged weight-bearing activity if advised by the clinician
• Use ice or other comfort measures if recommended
• Monitor for swelling, pain, redness, fever, or worsening symptoms
• Contact the clinic promptly with concerning symptoms
• Continue appropriate knee OA management as directed

Patients should be told that mild temporary discomfort can occur after injection. Severe or worsening pain, significant swelling, fever, spreading redness, or inability to bear weight should be evaluated promptly.

Safety Profile and Side Effects

Synvisc-One is a medical device used in a clinical setting and can cause side effects. Many adverse effects are localized and temporary, but serious complications can occur.

Common Temporary Side Effects

Common temporary effects may include:

• Pain or discomfort in the injected knee
• Swelling
• Warmth
• Redness
• Bruising
• Stiffness
• Temporary increase in knee pain

Less Common but Serious Concerns

Less common or more serious concerns may include:

• Joint infection
• Allergic reaction
• Severe or persistent swelling
• Severe pain
• Significant inflammatory reaction
• Skin changes or open sores near the treatment area
• Worsening function or inability to bear weight

Patients should contact the clinic urgently or seek appropriate medical care if they experience severe pain, marked swelling, fever, chills, spreading redness, drainage, rash, breathing symptoms, or any signs of infection or allergic reaction.

Synvisc-One vs. Corticosteroid Injections

Synvisc-One and corticosteroid injections are different treatment categories. Corticosteroid injections are generally used for short-term inflammatory symptom relief, while Synvisc-One is a viscosupplement intended to support the properties of joint fluid in selected patients.

The best option depends on diagnosis, symptom pattern, comorbidities, prior treatment response, guideline considerations, insurance coverage, and clinician judgment.

Clinics should avoid stating that one treatment is always preferred over the other. Shared decision-making and guideline-aware care are important.

Synvisc-One in a Broader Knee OA Management Plan

Knee OA management is usually multimodal. Synvisc-One should be considered as one possible component of care rather than a stand-alone solution.

A broader plan may include:

• Patient education
• Exercise and strengthening programs
• Physical therapy
• Weight management when appropriate
• Activity modification
• Bracing or assistive devices
• Topical or oral medications when appropriate
• Other injection options
• Orthopedic referral when symptoms or structural changes warrant it

Patients with advanced OA, severe deformity, mechanical symptoms, or progressive functional limitation may require orthopedic evaluation for additional treatment options.

Sourcing Synvisc-One for Professional Use

Health Supplies Plus offers professional orthopedic injectables for qualified clinics and licensed healthcare professionals. Reliable sourcing is important for product authenticity, storage integrity, inventory management, lot tracking, and patient safety.

When purchasing orthopedic injectables, clinics should verify:

• Supplier reputation and professional eligibility requirements
• Product authenticity
• Packaging integrity
• Lot number and expiration date
• Storage and handling requirements
• Product labeling and documentation
• Regulatory status in the clinic’s jurisdiction

Shop professional orthopedic injectables at Health Supplies Plus.

Frequently Asked Questions About Synvisc-One

Conclusion

Synvisc-One is a single-injection hylan G-F 20 viscosupplement used for selected patients with knee osteoarthritis pain who have not responded adequately to conservative non-pharmacological therapy and simple analgesics. It may help some patients manage symptoms, but response varies and it should not be positioned as a cure or routine solution for every knee OA case.

For clinics, responsible Synvisc-One use depends on careful patient selection, guideline-aware decision-making, qualified administration, aseptic technique, informed consent, realistic expectations, and authentic sourcing.

Explore professional orthopedic injectables at Health Supplies Plus.

This content is intended for professional informational purposes only and does not replace medical advice, diagnosis, treatment, product-specific training, manufacturer instructions, legal guidance, regulatory guidance, payer policy review, or applicable clinical protocols. Synvisc-One and other orthopedic injectable treatments should only be administered by qualified healthcare professionals in accordance with local laws, product labeling, scope-of-practice rules, sterile technique, and appropriate standards of care.

Doris

About the Author: Doris Dickson is a specialist writer for Health Supplies Plus, focusing on the aesthetic medicine industry. She diligently researches cosmetic treatments and products to provide clear, concise information relevant to licensed medical professionals. Her work supports Health Supplies Plus’s commitment to being a reliable informational resource and trusted supplier for the aesthetic community.

Disclaimer: The content provided in this article is intended for informational purposes only and is directed towards licensed medical professionals. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment, nor does it constitute an endorsement of any specific product or technique. Practitioners must rely on their own professional judgment, clinical experience, and knowledge of patient needs, and should always consult the full product prescribing information and relevant clinical guidelines before use. Health Supplies Plus does not provide medical advice.